跳至主要内容

Medicilon was selected as the "2023 Shanghai Professional Technical Service Platform"

 On January 18, the Science and Technology Commission of Shanghai Municipality released the 2023 Shanghai Professional Technical Service Platform construction project list. There are only 29 platforms in Shanghai on the list.

Medicilon Preclinical Research (Shanghai) LLC, a subsidiary of Shanghai Medicilon Inc. (Medicilon), Nucleic Acid Drug R&D Service Platform was successfully selected!  This is the Science and Technology Commission of Shanghai Municipality's high recognition of Medicilon's technological innovation and R&D capabilities, and is also a spur and incentive for Medicilon to continuously improve its service levels.

2023 Shanghai Professional Technical Service Platform.webp

The Shanghai professional technical service platform is an important part of Shanghai's scientific and technological innovation service system. It is a scientific research entity built on the basis of enterprises, scientific research institutes, universities or other institutions with scientific and technological innovation capabilities.  It is oriented to the needs of scientific and technological innovation and economic and social development, and integrates various scientific and technological resources play a fundamental functional role in reducing the cost of scientific and technological innovation, promoting innovation-driven development, and creating a scientific and technological innovation ecosystem.

The Nucleic Acid Drug R&D Service Platform selected by Medicilon this time is an integrated and comprehensive platform integrating drug discovery, production and preclinical research.  Based on rigorous scientific attitudes, open technology platforms, advanced instruments and equipment, as well as one-stop services for nucleic acid drug discovery, screening and preclinical research, it can shorten the research and development cycle, improve drug research and development efficiency, reduce costs, and promote new drugs to quickly enter the clinical stage.

Technological innovation is not achieved in a day, but comes from years of R&D investment and research.  As a one-stop biopharmaceutical preclinical R&D service platform in China, Medicilon has always integrated technological innovation into development since its establishment nearly 20 years ago.  Medicilon has accumulated rich R&D experience in the fields of ADC, small nucleic acids, PROTAC, and GLP-1.  Medicilon has served more than 50 ADC clients and currently has more than 30 projects under development, has served more than 40 small nucleic acid clients and has more than 20 projects under development, has served more than 30 PROTAC-related customers and nearly 20 projects are under development, and has also helped 8 GLP-1 related drugs obtain clinical approval.

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文